Overutilization of proton-pump inhibitors: What the clinician needs to know

Therapeutic Advances in Gastroenterology

Volumn 5, Issue 4, 2012, Pages 219-232

  Heidelbaugh, Joel J ^a   Kim, Andrea H ^b   Walker, Paul C ^c  

^a Ypsilanti Health Center   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Adverse risk; Cost effective; Overutilization; Proton pump inhibitors; Rebound acid hypersecretion

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CIMETIDINE; CLOPIDOGREL; CYANOCOBALAMIN; ESOMEPRAZOLE; FAMOTIDINE; IRON; MAGNESIUM; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RANITIDINE; SUCRALFATE;

AMBULATORY CARE; CELL HYPERPLASIA; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG MISUSE; DRUG SAFETY; DYSPEPSIA; ENTEROCHROMAFFIN LIKE CELL HYPERPLASIA; EVIDENCE BASED MEDICINE; FRACTURE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HOSPITAL CARE; HOSPITAL PATIENT; HUMAN; HYPERGASTRINEMIA; INAPPROPRIATE PRESCRIBING; INTESTINE INFECTION; NUTRITIONAL DEFICIENCY; OUTPATIENT CARE; PEPTIC ULCER; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SIDE EFFECT; STOMACH ACID SECRETION; STOMACH PARIETAL CELL HYPERTROPHY; STRESS ULCER; UPPER GASTROINTESTINAL TRACT;

EID: 84863486753     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X12437358     Document Type: Article

References (82)

1. Allen M.E. Kopp B.J. Erstad B.L. (2004) Stress ulcer prophylaxis in the postoperative period. Am J Health Syst Pharm 61: 588–596.
2. American Society of Health System Pharmacists (ASHP) (1999) ASHP therapeutic guidelines on stress ulcer prophylaxis. Am J Health Syst Pharm 56: 347–379.
3. Andres E. Loukili N. Noel E. Kaltenbach G. Ben Abdelgheni M. Perrin A.E. (2004) Vitamin B 12 (cobalamin) deficiency in elderly patients. CMAJ 171:251–259.
4. Aseeri M. Schroeder T. Kramer J. Zackula R. (2008) Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium-difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol 103: 2308–2313.
5. Bashford J.N. Norwood J. Chapman S.R. (1998) Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. BMJ 317: 452–456.
6. Bhatt D.L. Cryer B.L. Contant C.F. Cohen M. Lanas A. Schnitzer T.J. et al. (2010) Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 363: 1909–1917.
7. Bo-Linn G.W. Davis G.R. Buddrus D.J. Morawski S.G. Santa Ana C. Fordtran J.S. (1984) An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest 73: 640–647.
8. Cash B.D. (2002) Evidence-based medicine as it applies to acid suppression in the hospitalized patient. Crit Care Med 30(Suppl. 6): S373–S378.
9. Conrad S.A. Gabrielli A. Margolis B. Quartin A. Hata J.S. Frank W.O. et al. (2005) Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. Crit Care Med 33: 760–765.
10. Cook D.J. Fuller H.D. Guyatt G.H. Marshall J.C. Leasa D. Hall R. et al. for the Canadian Critical Care Trials Group (1994) Risk factors for gastrointestinal bleeding in critically ill patients. N Engl J Med 330: 377–381.
11. Cuisset T. Frere C. Quilici J. Poyet R. Gaborit B. Bali L. et al. (2009) Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose. The PACA (Proton Pump Inhibitors and Clopidogrel Association) Prospective Randomized Study. J Am Coll Cardiol 54: 1149–1153.
12. Cunningham R. Dale B. Undy B. Gaunt N. (2003) Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 54: 243–245.
13. Daley R.J. Rebuck J.A. Welage L.S. Rogers F.B. (2004) Prevention of stress ulceration: current trends in critical care. Crit Care Med 32: 2008–2013.
14. den Elzen W.P. Groeneveld Y. de Ruijter W. Souverijn J.H. le Cessie S. Assendelft W.J. et al. (2008) Long-term use of proton pump inhibitors and vitamin B 12 status in elderly individuals. Aliment Pharmacol Ther 27: 491–497.
15. de Vault K.R. Castell D.O. (2005) Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 100: 190–200.
16. Devlin J.W. Welage L.S. Olsen K.M. (2005 a) Proton pump inhibitor formulary considerations in the acutely ill. Part 1: pharmacology, pharmacodynamics, and available formulations. Ann Pharmacother 39: 1667–1677.
17. Devlin J.W. Welage L.S. Olsen K.M. (2005 b) Proton pump inhibitor formulary considerations in the acutely ill. Part 2: clinical efficacy, safety, and economics. Ann Pharmacother 39: 1844–1851.
18. Dial S. Alrasadi K. Manoukian C. Huang A. Menzies D. (2004) Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 171: 33–38.
19. Dial S. Delaney J.A.C. Barkun A.N. Suissa S. (2005) Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 294: 2989–2995.
20. Drug Topics (2011) Pharmacy Facts and Figures. (accessed 5 November 2011).
21. Farina C. Gagliardi S. (2002) Selective inhibition of osteoclast vacuolar H+-ATPase. Curr Pharm Des 8: 2033–2048.
22. Food and Drug Administration (FDA) (2009) Updated Safety Information about a Drug Interaction between Clopidogrel Bisulfate and Omeprazole. Public Health Advisory. (accessed 15 December 2011).
23. Food and Drug Administration (FDA) (2011) Low Magnesium Levels Can Be Associated with Long-term Use of Proton Pump Inhibitor drugs (PPIs). FDA Drug Safety Communication. Available at: http://www.fda.gov/drugs/drugsafety/ucm245011.htm (accessed 16 December 2011).
24. Forgacs I. Loganayagam A. (2008) Overprescribing proton pump inhibitors is expensive and not evidence based. BMJ 336: 2–3.
25. Gilard M. Arnaud B. Cornily J.C. Le Gal G. Lacut K. Le Calvez G. et al. (2008) Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. The randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J Am Coll Cardiol 51: 256–60.
26. Gill S.K. O'Brien L. Einarson T.R. Koren G. (2009) The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol 104: 1541–1545.
27. Gray S.L. La Croix A.Z. Larson L. Robbins J. Cauley J.A. Manson J.E. et al. (2010) Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women. Arch Int Med 170: 765–771.
28. Guillamondegui O.D. Gunter O.L. Jr Bonadies J.A. Coates J.E. Kurek S.J. de Moya M.A. et al. (2008) Practice Management Guidelines for Stress Ulcer Prophylaxis. Chicago, IL: Eastern Association for the Surgery of Trauma (EAST).
29. Gulmez S.E. Holm A. Frederiksen H. Jensen T.G. Pedersen C. Hallas J. (2007) Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Int Med 167: 950–955.
30. Havu N. (1986) Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 35(Suppl. 1): 42–55.
31. Heidelbaugh J.J. Goldberg K.L. Inadomi J.M. (2009) Adverse risks associated with proton pump inhibitors: a systematic review. Gastroenterol Hepatol 5: 725–734.
32. Heidelbaugh J.J. Goldberg K.L. Inadomi J.M. (2010) Magnitude and economic impact of overutilization of antisecretory therapy in the ambulatory care setting. Am J Manag Care 16: e228–e234.
33. Heidelbaugh J.J. Inadomi J.M. (2006) Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-intensive care unit hospitalized patients. Am J Gastroenterol 101: 2200–2205.
34. Ho P.M. Maddox T.M. Wang L. Fihn S.D. Jesse R.L. Peterson E.D. et al. (2009) Risk of adverse outcome associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301: 937–944.
35. Howden C.W. (2000) Vitamin B 12 levels during prolonged treatment with proton pump inhibitors. J Clin Gastroenterol 30: 29–33.
36. Howden C.W. Hunt R.H. (1987) Relationship between gastric secretion and infection. Gut 28: 96–107.
37. Hussain S. Stefan M. Visintainer P. Rothberg M. (2010) Why do physicians prescribe stress ulcer prophylaxis to general medicine patients? South Med J 103: 1103–1110.
38. IMS Health Report (2008) US Prescription Sales Grew 3.8 percent in 2007, to $286.5 billion. (accessed 5 November 2011).
39. Inadomi J.M. (2002) On-demand and intermittent therapy for gastro-esophageal reflux disease. Pharmaco Economics 20: 565–576.
40. Inadomi J.M. Jamal R. Murata G.H. Hoffman R.M. Lavezo L.A. Vigil J.M. et al. (2001) Step-down management of gastroesophageal reflux disease. Gastroenterology 121: 1095–1100.
41. Inadomi J.M. McIntyre L. Bernard L. Fendrick A.M. (2003) Step-down from multiple- to single-dose proton pump inhibitors (PPIS): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIS. Am J Gastroenterol 98: 1940–1944.
42. Jacobson B.C. Ferris T.G. Shea T.L. Mahlis E.M. Lee T.H. Wang T.C. (2003) Who is using chronic acid suppression therapy and why? Am J Gastroenterol 98: 51–58.
43. Jayatilaka S. Shakov R. Eddi R. Bakaj G. Baddoura W.J. de Bari V.A. (2007) Clostridium difficile infection in an urban medical center: five-year analysis of infection rates among adult admissions and association with the use of proton pump inhibitors. Ann Clin Lab Sci 37: 241–247.
44. Jianu C.S. Lange O.J. Viset T. Qvigstad G. Martinsen T.C. Fougner R. et al. (2012) Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor. Scand J Gastroenterol 47: 64–67.
45. Judd W.R. Davis G.A. Winstead P.S. Steinke D.T. Clifford T.M. Macaulay T.E. (2009) Evaluation of continuation of stress ulcer prophylaxis at hospital discharge. Hosp Pharm 44: 888–893.
46. Kahrilas P.J. Shaheen N.J. Vaezi M.F. (2008) American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology 135: 1383–1391.
47. Kantorova I. Svoboda P. Scheer P. Doubek J. Rehorkova D. Bosakova H. et al. (2004) Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial. Hepatogastroenterology 51: 757–761.
48. Kaye J.A. Jick H. (2008) Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 28: 951–959.
49. Laheij R.J.F. Sturkenboom M.C.J.M. Hassing R.J. Dieleman J. Stricker B.H.C. Jansen J.B.M.J. (2004) Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 292: 1955–1960.
50. Lamberts R. Creutzfeldt W. Stockmann F. Jacubaschke U. Maas S. Brunner G. (1988) Long-term omeprazole treatment in man: effects on gastric endocrine cell populations. Digestion 39: 126–135.
51. Leonard J. Marshall J.K. Moayyedi P. (2007) Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 102: 2047–2056.
52. Levy M.J. Seelig C.B. Robinson N.J. Ranney J.E. (1997) Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. Dig Dis Sci 42: 1255–1259.
53. Lin P. Chang C. Hsu P. Tseng P. Huang Y. (2010) The efficacy and safety of proton pump inhibitors vs. histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis. Crit Care Med 38: 1197–1205.
54. Loo V.G. Bourgault A.M. Poirier L. Lamothe F. Michaud S. Turgeon N. et al. (2011) Host and pathogen factors for Clostridium difficile infection and colonization. N Eng J Med 365: 1693–1703.
55. Marik P.E. Vasu T. Hirani A. Pachinburavan M. (2010) Stress ulcer prophylaxis in the new millennium: a systematic review and meta-analysis. Crit Care Med 38: 2222–2228.
56. Metz D.C. (2008) Clostridium difficile colitis: wash your hands before stopping the proton pump inhibitor. Am J Gastroenterol 103: 2314–2316.
57. Metz D.C. Inadomi J.M. Howden C.W. van Zanten S.J. Bytzer P. (2007) On- demand therapy for gastroesophageal reflux disease. Am J Gastroenterol 102: 642–653.
58. Murphy C.E. Stevens A.M. Ferrentino N. Crookes B.A. Hebert J.C. Freiburg C.B. et al. (2008) Frequency of inappropriate continuation of acid suppressive therapy after discharge in patients who began therapy in the surgical intensive care unit. Pharmacotherapy 28: 968–976.
59. Nardino R.J. Vender R.J. Herbert P.N. (2000) Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol 95: 3118–3122.
60. Niklasson A. Lindström L. Simrén M. Lindberg G. Bjornsson E. (2010) Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol 105: 1531–1537.
61. Pasternak B. Hviid A. (2010) Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med 363: 2114–2123.
62. Pham C.Q.D. Regal R.E. Bostwick T.R. Knauf K.S. (2006) Acid suppressive therapy use on an inpatient internal medicine service. Ann Pharmacother 40: 1261–1266.
63. Poulsen A.H. Christensen S. McLaughlin J.K. Thomsen R.W. Sorensen H.T. Olsen J.H. et al. (2009) Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. Br J Cancer 100: 1503–1507.
64. Quenot J.P. Thiery N. Barbar S. (2009) When should stress ulcer prophylaxis be used in the ICU? Curr Opin Crit Care 15: 139–143.
65. Reimer C. Sondergaard B. Hilsted L. Bytzer P. (2009) Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 137: 80–87.
66. Sarkar M. Hennessy S. Yang Y.X. (2008) Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Int Med 149: 391–398.
67. Sheen E. Triadafilopoulos G. (2011) Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci 56: 931–950.
68. Siller-Matula J.M. Spiel A.O. Lang I.M. Kreiner G. Christ G. Jilma B. et al. (2009) Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 157: 148.e1–148.e5.
69. Stewart C.A. Termanini B. Sutliff V.E. Serrano J. Yu F. Gibril F. et al. (1998) Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther 12: 83–98.
70. Stollman N. Metz D.C. (2005) Pathophysiology and prophylaxis of stress ulcer in intensive care unit patients. J Crit Care 20: 35–45.
71. Talley N. (2005) American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology 129: 1753–1755.
72. Targownik L.E. Lix L.M. Leung S. Leslie W.D. (2010) Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 138: 896–904.
73. Targownik L.E. Lix L.M. Metge C.J. (2008) Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 179: 319–326.
74. Thachil J. (2008) Overprescribing PP Is: time for a hospital antacid policy on Clostridium difficile. BMJ 336: 109.
75. Thomas L. Culley E.J. Gladowski P. Goff V. Fong J. Marche S.M. (2010) Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization. J Manag Care Pharm 16: 122–129.
76. Valuck R.J. Ruscin J.M. (2004) A case-control study on adverse effects: H 2 blocker or proton pump inhibitor use and risk of vitamin B 12 deficiency in older adults. J Clin Epidemiol 57: 422–428.
77. Vestergaard P. Rejnmark L. Mosekilde L. (2006) Proton pump inhibitors, histamine h (2) receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 79: 76–83.
78. Waldum H.L. Arnestad J.S. Brenna E. Eide I. Syversen U. Sandvik A.K. (1996) Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 39: 649–653.
79. Waldum H.L. Brenna E. Sandvik A.K. (2002) Long-term safety of proton pump inhibitors: risks of gastric neoplasia and infections. Expert Opin Drug Saf 1: 29–38.
80. Wohlt P.D. Hansen L.A. Fish J.T. (2007) Inappropriate continuation of stress ulcer prophylactic therapy after discharge. Ann Pharmacother 41: 1611–1616.
81. Yang Y.X. Lewis J.D. Epstein S. Metz D.C. (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296: 2947–2953.
82. Zink D.A. Pohlman M. Barnes M. Cannon M.E. (2005) Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther 21: 1203–1209.